Pacira pain drug succeeds in late-stage trial

Thu Feb 27, 2014 7:07am EST

Feb 27 (Reuters) - Pacira Pharmaceuticals Inc said a late-stage trial testing its drug Exparel for a wider use showed the treatment significantly reduced pain compared to placebo in knee surgery patients.

Exparel is already approved for use in managing post-surgical pain when administered directly at the site of the pain. The latest trial was testing Exparel's efficacy when applied to a major nerve adjacent to the site of the surgery, thereby blocking any sensation until the nerve endings.

A late-stage trial testing the drug, Exparel, showed that patients taking the medicine experienced significant reduction in pain over 72 hours.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.